Insider buying, volume, trial results

Long with a small position established. Financials are looking good to 2025 with enough cash to meet demands of trials. Leading up to the osteogenesis imperfecta results was large cluster insider buying along with sentiment from CEO at interviews leading up to results being extremely positive. Volume pick up and bullish engulfing on the weekly looking to move off of the positive results. Exciting times ahead.